Dr Reddy's Labs PAT likely to soar 55.5% in Q3

Pharmaceutial firm Dr Reddy's Laboratories is expected to report a profit after tax of Rs 425 crore in the third quarter of FY12, a massive growth of 55.5% as compared to Rs 273 crore in a year ago quarter.

February 03, 2012 / 11:56 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Pharmaceutial firm Dr Reddy's Laboratories is expected to report a profit after tax of Rs 425 crore in the third quarter of FY12, a massive growth of 55.5% as compared to Rs 273 crore in a year ago quarter.

Revenues are seen going up by 35% to Rs 2,562 crore from Rs 1,899 crore year-on-year.

EBITDA is likely to go up by 103% to Rs 596 crore versus Rs 293.4 cr during the same period.

Operating profit margin is expected to be improving at 23% versus 15.5% year-on-year and 16.5% quarter-on-quarter.

On quarter-on-quarter basis, revenues are seen going up by 13% and EBITDA by 59%. Profit after tax is likely to shot up 38%.

Watch out for:

- US business driven by exclusivity will be a key growth driver, hence ripple effect on margins & bottomline

- DRL launched Zyprexa generic with 180 day exclusivity

first published: Feb 3, 2012 10:05 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.